Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 7/20 | 0.42 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.42 |
| ▸ | PTGFR | P43088 | 1/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.35 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16843276 | 1.00 | SLC6A11 (0.42) | SLC6A11SLC6A1PTGFRSLC6A12MEN1 | |
| SCHEMBL17231722 | 1.00 | SLC6A11 (0.42) | SLC6A11SLC6A1PTGFRSLC6A12MEN1 | |
| SCHEMBL9604514 | 1.00 | SLC6A11 (0.42) | SLC6A11SLC6A1PTGFRSLC6A12MEN1 | |
| SCHEMBL26302691 | 0.94 | SLC6A11 (0.42) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL14978147 | 0.94 | SLC6A11 (0.42) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL14977891 | 0.94 | SLC6A11 (0.42) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL26302685 | 0.94 | SLC6A11 (0.42) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL26302681 | 0.94 | SLC6A11 (0.42) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL9908638 | 0.94 | SLC6A11 (0.42) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL16248722 | 0.93 | SLC6A11 (0.44) | SLC6A11SLC6A1SLC6A12MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| EP-3992291-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | GALNT6, GALNT3, GALNT14 | SLC6A11 3947/4885SLC6A1 4032/4885PTGFR 3537/4885 |
| US-11840691-B2 | Compound and application thereof | GALNT6, GALNT3, GALNT14 | SLC6A11 3924/4885SLC6A1 3975/4885PTGFR 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.